Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health, Wuxi Government Form Joint Venture for Liver Cancer Screening Test

NEW YORK – Precision oncology firm Genetron Health said last week that it has formed a joint venture and created a new operating center with China's Wuxi municipal government to advance its liver cancer early detection assay, HCCscreen.

Wuxi — a city in the southern part of Jiangsu Province in eastern China with a population of over 6 million people — has committed to using HCCScreen for its residents and will provide Genetron Health with other supportive measures including subsidies and tax benefits. Both parties are contributing capital and Genetron Health will own 90 percent of the venture.

Alongside the joint venture agreement, Genetron said that HCCScreen has been selected by the Chinese National Cancer Center and the Wuxi municipal government for use in a public health initiative called the Liver Cancer Early Screening Comprehensive Prevention and Control Project, which is expected to generate real-world data that would further support the test's commercialization.

The two parties had previously entered into a small-scale collaboration agreement, and the new initiative represents an expansion of that partnership. According to Beijing-based Genetron, Wuxi is committed to administering 150,000 tests to residents over a period of three years.

Sizhen Wang, Genetron Health’s cofounder and CEO, said in a statement that the effort "represents a major milestone for HCCscreen as it will be broadly used in a real-world setting, reflecting its clinical value that both the NCC and Wuxi recognized.

"Wuxi’s investment and other supportive measures also highlight its commitment to advancing the liver cancer early screening in China … [and] overall, we expect this initiative to ultimately help drive faster adoption," he added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.